We report the case of a 15-year-old previously thalassemic girl who, 15 months after allogeneic BMT, developed HBeAg-negative hepatitis B (variant with mu-1896). In the absence of another route of transmission, HBV reactivation is postulated. The time of emergence of the HBV variant (with mu-1896) is probably related to the development of anti-HBe immunity. This mutant strain is associated with fulminant hepatitis. The patient achieved complete remission and HBV eradication despite having moderate GVHD and receiving immunosuppressive therapy. Keywords: bone marrow transplantation; HBV mutant; HBV reactivation Bone marrow graft recipients have prolonged cellular and humoral immunodeficiencies, especially if they develop chronic graft-versus-host disease (GVHD).
Bone marrow graft recipients have prolonged cellular and humoral immunodeficiencies, especially if they develop chronic graft-versus-host disease (GVHD). 1 Recovery from HBV infection is dependent on the integrated function of the patient's immune system and heterogeneity of the viral population. 2, 3 Immunocompromised patients, especially those with disturbances in interferons, cytotoxic T lymphocytes, natural killer cells, CD4
+ and CD8 + lymphocytes are at increased risk of developing chronic infections. 4, 5 Infection by the HBV viral population containing high amounts of mutants referred to as HBeAg-minus viruses (mu-1896) results more frequently in severe or fulminant hepatitis. 6, 7 We report the course of HBeAg-negative hepatitis in a previously thalassemic girl receiving immunosuppressive therapy for chronic GVHD.
Case report
In November 1993, a 14-year-old girl with ␤-thalassemia major underwent allogeneic BMT from her HLA-identical sister. The patient engrafted promptly, but she developed moderate chronic GVHD, involving mainly the skin and Correspondence: S Kostaridou, First Department of Pediatrics, Aghia Sophia Children's Hospital, Thivon and M Asias, 115 27 Athens, Greece Received 19 January 1998; accepted 20 June 1998 pulmonary tract. GVHD was treated with methylprednisolone, azathioprine and cyclosporin A, which were slowly tapered off over 1 year. Fourteen months after BMT she developed exacerbation of pulmonary GVHD, which was treated with reinstitution of high-dose methylprednisolone and cyclosporin A. Soon after, she developed asymptomatic mild hepatomegaly and elevation of serum transaminases. Serum levels of alanine aminotransferase (ALT) were 603 U/l (normal range 5-45), of aspartate aminotransferase (AST) 201 U/l (normal range 10-60), and of ␥-glutamyl transferase (␥-GT) 153 U/l (normal value Ͻ35) while the levels of alkaline phosphatase and bilirubin were within the normal range. There was no serological evidence of acute CMV, EBV, HCV, HAV and HIV infection. hepatitis A, B or C infection. The patient had not had any recent transfusions of blood products, apart from intravenous immunoglobulins. The last transfusion of packed red blood cells was during the first month post BMT. Based on the laboratory and clinical findings, a diagnosis of acute HBV was made. Cyclosporin A was gradually discontinued and the dose of methylprednisolone was reduced, without significant GVHD aggravation. In the following 3 months, there was a marked deterioration of liver function tests suggestive of fulminant hepatitis. More specifically, the serum levels of ALT reached 4440 IU/l, AST reached 2610 IU/l, ␥GT reached 1120 IU/l and total bilirubin reached 5.7 mg/dl (Figure 1) .
Serological re-examination revealed HBeAg/anti-HBe seroconversion, which usually reflects a state of low or absent HBV replication. Two months later, despite the absence of HBeAg, there was persistent evidence of viral replication (HBV DNA = 90 pg/ml) along with high antiHBc (IgM) titers (2749 EU). Liver biopsy was performed and histological evaluation revealed chronic active hepatitis with mild alteration of bile ducts (which may have been due to GVHD), and grade I fibrosis. Immunohistochemical reactions showed nuclear positivity of HBcAg. This serological profile indicated changes in the genome of the virus. Therefore, the nucleotide sequence of the precore region of HBV DNA was determined by direct DNA sequencing analysis. For this purpose, a segment of the viral DNA was amplified by PCR, using primers that flank the precore/core region of the virus, as previously described. 7 The prevalent mutation at nucleotide 1896 (G to A) was found in two separate serum samples. This HBV variant is unable to produce HBeAg. 8 In HBV infection, HBeAg induces and maintains specific immune tolerance to HBV replication. Therefore, failure of this variant to produce HBeAg is associated with inadequate immune tolerance and consequently, greater possibility of clearance of the virus and higher incidence of fulminant hepatitis. [6] [7] [8] During this period, the dose of steroids was increased in order to attenuate the immune reaction and severity of hepatic damage. Following the decrease of serum transaminase levels, steroids were slowly tapered off. Six months from the onset, the levels of ALT, AST, ␥GT and bilirubin normalized (Figure 1 ). Serum HBV markers showed complete remission of the hepatitis (anti-HBs = positive) and PCR analysis showed viral eradication (HBV DNA = negative).
Two and a half years after the hepatitis, the patient remains in good health with stable GVHD, mild skin lesions and subclinical pulmonary impairment. She has normal ALT, AST levels and HBV immunity markers (HBsAg = negative, anti-HBc = positive and anti-HBs = positive).
Discussion
Infection with HBV during BMT is due either to viral transmission by contaminated blood products or bone marrow, or to reactivation of a previous infection. [9] [10] [11] Even though BMT recipients may be more susceptible in acquiring blood-born viruses, the current practices for blood product and donor screening have rendered transmission of HBV by transfusions rare. 12 Reactivation of HBV during immunosuppressive therapy for hematological malignancies or BMT has been previously described. [9] [10] [11] [12] [13] In some of these cases, anti-HBs and/or anti-HBc were initially detected, suggestive of a past cleared HBV infection. In these HBV immune patients, the loss of anti-HBs and/or anti-HBc after transplantation, has been associated with the re-appearance of HBsAg and reactivation of hepatitis. 12 HBV DNA sequences have been detected in serum, liver or hepatic tumor tissue, even in the absence of HBsAg. 14, 15 These observations indicate that HBV infection may exist in a dormant state as a latent or occult chronic infection. The previously thalassemic patient documented in this report developed asymptomatic acute hepatitis B 15 months after BMT. As her recent clinical history did not indicate any possible sources of exogenous transmission, reactivation of either a latent infection or an occult chronic infection is speculated.
Mutations in the precore region of HBV DNA may abolish the production of HBeAg. The most common mutation in HBeAg-minus variant encountered in the Mediterranean area is a G to A change at nucleotide 1896 (mu-1896), which creates a novel stop codon. 16 This mu-1896 HBV variant was identified in our patient by direct sequencing of PCR-amplified serum HBV DNA. The induction and maintenance of immune tolerance are likely to be an effect of HBeAg. 16 HBeAg-minus viruses can coexist together with the wild type of HBV as a minor quasi-species. They become prominent when anti-HBe immunity develops and may replicate, survive and transmit infection to new hosts. HBeAg-negative chronic hepatitis B does not represent a unique disease entity, but rather, a specific phase in the natural course of HBV infection, whose time of emergence seems to vary widely. 16 Failure of the HBeAg-minus viruses to produce HBeAg appears to influence the outcome of primary HBV infection and is associated with a stronger immune response, a higher chance of clearing the virus, and a higher incidence of fulminant hepatitis.
Allogeneic BMT recipients are in a prolonged immunodeficient state after transplant. Their immune system slowly progresses from a primitive state of predominance of cells with suppressive function to the normal state of fine interactions between the different components of immune activity. 1 Recovery from HBV infection requires both humoral and cell-mediated immune responses. 17 The course of HBV infection in immunocompromised patients is variable and there is a high possibility of developing chronic hepatitis B. Furthermore, immunosuppressive therapy has been shown to enhance viral replication in patients with chronic hepatitis B.
18 Therefore, we initially reduced the immunosuppressive therapy in our patient, in order to induce a more vigorous immune response and higher likelihood of viral elimination. During the course of the disease, the emergence of HBeAg-negative hepatitis and the associated risk of fulminant hepatitis, we re-instituted a more aggressive immunosuppressive regimen. The changes in immunosuppressive therapy may have contributed in preventing massive liver necrosis, and in successfully eradicating HBV.
This case illustrates the possibility of HBV infection in the post-transplant period, despite the absence of an exogenous source. HBeAg-minus variant may emerge dur-ing the course of hepatitis. Timely detection of this variant assists in better appreciation of the clinical course and in the institution of an appropriate therapeutic regimen.
